[Determination of Iodine-125 labelled monoclonal ras oncoprotein in plasma from non-smoking female lung cancer patients and healthy controls.].
To explore the significance of oncoprotein in plasma in the carcinogenic process of lung cancer. ras oncoprotein in plasma was assayed in 38 lung cancer patients and 59 healthy women for controls among non-smoking females by Western Blot analysis with monoclonal ras antibody as the primary antibody and iodine-125 labelled technique. Positive samples were found in 35 of the 38 patients versus 17 of the 59 controls , odds ratio (OR) was 28.8 (Chi-Square MH = 36.85) . OR for 35 positive samples with 23(+),8(++),4(+++) was 21.5 , 112.0 and 56.0 respectively (Chi-Square MH = 27.45 ,30.58 and 19.70) . ras oncoprotein levels of the plasma from the lung cancer patients were statistically significantly higher than those from the controls ( P < 0.001) . An increasing of ras oncoprotein in plasma could be a possible biomarker of epidemiologic study for female lung cancer. ras oncoprotein may be used to health surveillance of high-risk population due to environmental and occupational exposure.